Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome

Objectives: Elevated circulating branched-chain amino acids (BCAAs) have been associated with obesity, insulin resistance, and MASLD. Nonetheless, BCAA supplementation has been shown to provide protective outcomes towards the intervention of MASLD. Currently, there is a lack of study towards the con...

Full description

Saved in:
Bibliographic Details
Main Authors: Felicianna, Emily K.K. Lo, Congjia Chen, Marsena J. Ismaiah, Fangfei Zhang, Hoi Kit Matthew Leung, Hani El-Nezami
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Molecular Metabolism
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221287782400190X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846160443177959424
author Felicianna
Emily K.K. Lo
Congjia Chen
Marsena J. Ismaiah
Fangfei Zhang
Hoi Kit Matthew Leung
Hani El-Nezami
author_facet Felicianna
Emily K.K. Lo
Congjia Chen
Marsena J. Ismaiah
Fangfei Zhang
Hoi Kit Matthew Leung
Hani El-Nezami
author_sort Felicianna
collection DOAJ
description Objectives: Elevated circulating branched-chain amino acids (BCAAs) have been associated with obesity, insulin resistance, and MASLD. Nonetheless, BCAA supplementation has been shown to provide protective outcomes towards the intervention of MASLD. Currently, there is a lack of study towards the contribution of the BCAA: valine on MASLD. Herein, the effect of low-dose valine supplementation was investigated for its role in the progression of MASLD. Methods: C57BL/6J mice were fed a high-fat/high-cholesterol diet (HFD) to induce MASLD. Upon the establishment of MASLD, valine was supplemented via voluntary oral administration. Clinical and biochemical parameters associated with MASLD were measured, and molecular mechanism and gut microbiota modulation from the effect of valine were investigated. Results: Low-dose valine was found to attenuate the progression of MASLD, significantly reducing the gain in body weight, liver weight, and epididymal white adipose tissue (eWAT) weight, while also attenuating hyperglycemia and hyperleptinemia, and improving serum lipid profiles. Mechanistically, in the liver, genes related to hepatic lipogenesis and cholesterol biosynthesis were downregulated, while those associated with fatty acid oxidation, autophagy, and antioxidant capacity were upregulated, and AMPK pathway activity was enhanced. Liver and hypothalamic leptin resistance and inflammation were also attenuated, allowing better appetite control in mice fed a HFD and leading to reduced food intake. Additionally, metabolic flexibility in the eWAT was improved, and the gut microbiome was modulated by low-dose valine supplementation. Conclusion: Low-dose valine supplementation attenuates MASLD by enhancing systemic leptin sensitivity and modulating the gut microbiome.
format Article
id doaj-art-fa5bedd5c25240f1a2a4e9f031fe4cc0
institution Kabale University
issn 2212-8778
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Molecular Metabolism
spelling doaj-art-fa5bedd5c25240f1a2a4e9f031fe4cc02024-11-22T07:37:07ZengElsevierMolecular Metabolism2212-87782024-12-0190102059Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome Felicianna0Emily K.K. Lo1Congjia Chen2Marsena J. Ismaiah3Fangfei Zhang4Hoi Kit Matthew Leung5Hani El-Nezami6School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, ChinaSchool of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, ChinaSchool of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, ChinaSchool of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, ChinaSchool of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, ChinaSchool of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, ChinaSchool of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China; Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, FI-70211 Kuopio, Finland; Corresponding author. School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China.Objectives: Elevated circulating branched-chain amino acids (BCAAs) have been associated with obesity, insulin resistance, and MASLD. Nonetheless, BCAA supplementation has been shown to provide protective outcomes towards the intervention of MASLD. Currently, there is a lack of study towards the contribution of the BCAA: valine on MASLD. Herein, the effect of low-dose valine supplementation was investigated for its role in the progression of MASLD. Methods: C57BL/6J mice were fed a high-fat/high-cholesterol diet (HFD) to induce MASLD. Upon the establishment of MASLD, valine was supplemented via voluntary oral administration. Clinical and biochemical parameters associated with MASLD were measured, and molecular mechanism and gut microbiota modulation from the effect of valine were investigated. Results: Low-dose valine was found to attenuate the progression of MASLD, significantly reducing the gain in body weight, liver weight, and epididymal white adipose tissue (eWAT) weight, while also attenuating hyperglycemia and hyperleptinemia, and improving serum lipid profiles. Mechanistically, in the liver, genes related to hepatic lipogenesis and cholesterol biosynthesis were downregulated, while those associated with fatty acid oxidation, autophagy, and antioxidant capacity were upregulated, and AMPK pathway activity was enhanced. Liver and hypothalamic leptin resistance and inflammation were also attenuated, allowing better appetite control in mice fed a HFD and leading to reduced food intake. Additionally, metabolic flexibility in the eWAT was improved, and the gut microbiome was modulated by low-dose valine supplementation. Conclusion: Low-dose valine supplementation attenuates MASLD by enhancing systemic leptin sensitivity and modulating the gut microbiome.http://www.sciencedirect.com/science/article/pii/S221287782400190XValineMetabolic dysfunction-associated steatotic liver disease (MASLD)Lipid metabolismLeptin resistance
spellingShingle Felicianna
Emily K.K. Lo
Congjia Chen
Marsena J. Ismaiah
Fangfei Zhang
Hoi Kit Matthew Leung
Hani El-Nezami
Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
Molecular Metabolism
Valine
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Lipid metabolism
Leptin resistance
title Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
title_full Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
title_fullStr Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
title_full_unstemmed Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
title_short Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
title_sort low dose valine attenuates diet induced metabolic dysfunction associated steatotic liver disease masld in mice by enhancing leptin sensitivity and modulating the gut microbiome
topic Valine
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Lipid metabolism
Leptin resistance
url http://www.sciencedirect.com/science/article/pii/S221287782400190X
work_keys_str_mv AT felicianna lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome
AT emilykklo lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome
AT congjiachen lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome
AT marsenajismaiah lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome
AT fangfeizhang lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome
AT hoikitmatthewleung lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome
AT hanielnezami lowdosevalineattenuatesdietinducedmetabolicdysfunctionassociatedsteatoticliverdiseasemasldinmicebyenhancingleptinsensitivityandmodulatingthegutmicrobiome